Memphasys closes sale of gels business to Dycent Biotech

Workflow Solutions
Products
See more S&P Global Solutions
See More IHS Markit Solutions
Content
How We Can Help
See More
News & Insights Topics
See More
Featured Events
In PersonPolitics & Policy: Market Impacts and Mid-Year Outlooks
- 06/24/2022
- Sofitel Washington DC Lafayette Square
- 8:30 AM – 12:00 PM ET
Webinar ReplaysExpand Your Perspective: Analyzing Deal Activity & Drivers Across the Capital Markets
- 06/08/2022
- On-Demand
- 1 Hour
In Person451Nexus
- 10/03/2022
- ARIA Resort and Casino, Las Vegas, Nevada
- ARIA Resort and Casino
Platforms
Other Products
- Leveraged Commentary and Data
- Research Online

In This List

Blog

Commercial Banking: June 22nd Edition

Blog

Understanding Loss Given Default A Review of Three Approaches

Blog

Commercial Banking Newsletter June Edition - 2022

Blog

Insight Weekly: US recession outlook; mortgage activity slowdown; climate disclosure push

6 Apr, 2017 | 06:13

Author Vince Iral
Theme Healthcare & Pharmaceuticals

Memphasys Ltd. completed the sale of its gels business to Dycent Biotech (Shanghai) Co. Ltd.

The $130,000 deal includes Memphasys U.S. unit NuSep Inc., a manufacturing plant and related patents. The transaction was announced April 2016, when Memphasys was still known as NuSep Holdings Ltd.

The deal closed after Memphasys fulfilled the contractual requirement of commissioning of the gels manufacturing plant, which was relocated to Shanghai.